Introduction
============

Thyroid cancer is one of the most common types of endocrine malignancy, the incidence rate of which has rapidly increased during previous years ([@b1-mmr-14-06-5041],[@b2-mmr-14-06-5041]). It has been estimated that the annual number of cases of thyroid cancer diagnosed in the USA and the associated mortality rate are 12.9/100,000 and 0.5/100,000 individuals, respectively ([@b3-mmr-14-06-5041]). Papillary thyroid cancer (PTC), characterized by papillary architecture, psammoma bodies and specific nuclear features, including nuclear orientation, nuclear chromatin and nuclear grooving, is the major form of thyroid cancer, accounting for 80--85% of all thyroid malignancies ([@b4-mmr-14-06-5041]). Although PTC has a favorable prognosis, certain cases exhibit aggressive clinical characteristics, including invasion and metastasis, and the management of PTC remains controversial ([@b5-mmr-14-06-5041],[@b6-mmr-14-06-5041]). Therefore, it is essential to investigate the molecular mechanisms of PTC and identify potential biomarkers, which may be beneficial for improving treatment.

The current understanding of the molecular mechanisms of PTC has improved significantly, particularly with the development of next generation sequencing and microarray technology. It has been reported that mutations of BRAF (T1796A and V599E) causing the activation of serine/threonine kinase may be an alternative mechanism of oncogenic mitogen-activated protein kinase pathway activation and are important in the development of PTC ([@b7-mmr-14-06-5041]--[@b9-mmr-14-06-5041]). The chemokine receptor, CXCR7 not only activates the phosphoinositide 3-kinase/AKT and nuclear factor-κB signaling pathways, but it also downregulates the Notch signaling pathway to regulate the growth and metastasis of PTC, according to gene expression profiling analysis of PTC ([@b10-mmr-14-06-5041]). Amyloid precursor protein is overexpressed in PTC and may become a potential novel therapeutic target for PTC ([@b11-mmr-14-06-5041]). It has been revealed that certain important upregulated microRNAs (miRs), including miR-221, miR-222 and miR-146, and the regulation of KIT are involved in the pathogenesis of PTC, based on previous microarray analysis of GSE3467 ([@b12-mmr-14-06-5041]). Zhu *et al* ([@b13-mmr-14-06-5041]) showed that Trefoil factor 3, cut-like homeobox 2 and forkhead box protein A2 are associated with the development of PTC, and the differentially expressed genes (DEGs) are primarily associated with positive regulation of gene expression, gene transcription and metabolic processes.

In the previous study by Zhu *et al* ([@b13-mmr-14-06-5041]) only the GSE3678 DNA microarray data set was downloaded for DEG screening and subsequent enrichment analysis. In the present study, two DNA microarray data sets, GSE3467 and GSE3678, were combined for microarray analysis. The DEGs found to be simultaneously differentially expressed in the tumor samples of these two data sets were screened for enrichment analysis and interaction network construction. The potential drugs for the critical DEGs were also investigated. The present study may aid the diagnosis and treatment of PTC.

Materials and methods
=====================

Gene expression profiles. The two gene expression profiling data sets, GSE3467 and GSE3678, were downloaded from the Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo/>) ([@b14-mmr-14-06-5041]). GSE3467 ([@b12-mmr-14-06-5041]) consisted of 18 paired tumor and normal thyroid tissue samples from nine patients with PTC. The GSE3678 data set contained seven PTC samples and seven paired normal thyroid tissue samples. The platform used for these two data sets was the GPL570 \[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 array.

Data preprocessing and screening of DEGs. The probes without annotation of the gene expression profiles were filtered, and the probes were transformed into gene symbols. The average value of a gene symbol corresponding to multiple probes was calculated for the expression level analysis. The log2 transformation, background correction and data normalization were performed using the GeneChip Robust Multi-array Analysis (GCRMA) method within Bioconductor (<http://www.bioconductor.org>) ([@b15-mmr-14-06-5041]). The DEGs were screened out by using the Linear Models for Microarray Analysis (Limma) package in R software ([@b16-mmr-14-06-5041]) with the cut-off criteria of adjusted P\<0.01 and \|log2 fold-change (FC)\|\>2.

Functional and pathway enrichment analyses. Functional and pathway enrichment analyses for the common DEGs were performed using the Database for Annotation, Visualization and Integrated Discovery online tools ([@b17-mmr-14-06-5041]) based on the Gene Ontology (GO) ([@b18-mmr-14-06-5041]) and Kyoto Encyclopedia of Genes and Genomes ([@b19-mmr-14-06-5041]) databases. The GO terms in three categories, including biological process, cellular component and molecular function, were identified with P\<0.05. For pathway enrichment analysis, P≤0.05 was set as the threshold.

Construction and analysis of the protein-protein interaction (PPI) network. The physical PPIs and pathway interactions were selected for PPI network construction using the Gene Multiple Association Network Integration Algorithm (<http://www.genemania.org/>) ([@b20-mmr-14-06-5041]) plug-in of Cytoscape software ([www.cytoscape.org](www.cytoscape.org); version 3.4.0). The representative subnetwork containing nodes with high levels of interconnection was further derived from the PPI network using Molecular Complex Detection software ([baderlab.org/Software/MCODE](baderlab.org/Software/MCODE)) ([@b21-mmr-14-06-5041]). In addition, the potential drugs of the hub DEGs in the subnetwork were searched using the DrugBank database ([www.drugbank.ca](www.drugbank.ca)) ([@b22-mmr-14-06-5041]) and the potential drug-like ligands, which interacted with the genes, were screened from the diverse-lib database in MTiOpenScreen (bioserv.rpbs.univ-paris-diderot.fr/services/MTiOpenScreen) ([@b23-mmr-14-06-5041]) according to Lipinski\'s rule of five ([@b24-mmr-14-06-5041]).

Results
=======

Identification of DEGs. Following data preprocessing, the standardized expression profiling data showed that the median values of gene expression were almost at the same level, indicating that the degree of standardization was sufficient to be used for the subsequent analysis ([Fig. 1](#f1-mmr-14-06-5041){ref-type="fig"}). A total of 384 and 262 DEGs were identified for GSE3467 and GSE3678, respectively. In addition, 167 genes were found to be simultaneously differentially expressed in the tumor samples of these two data sets ([Fig. 2A](#f2-mmr-14-06-5041){ref-type="fig"}). Among these 167 common DEGs, 77 genes were upregulated and 90 genes were downregulated. The correlation of the expression values for the 167 genes was 0.97 (P\<2.2e-16; [Fig. 2B](#f2-mmr-14-06-5041){ref-type="fig"}).

Functional and pathway enrichment analysis. The common DEGs were primarily associated with the cellular components of the plasma membrane (P=2.60E-05) and integral to the membrane (P=0.002429). Certain common DEGs, including LC26A4, GABRB3, GABRB2 and CLCNKB, were significantly enriched in the anion transmembrane transporter activity (P=4.45E-04) and chloride anion binding (P=0.005756). In addition, SERPINA1, CITED1 and GHR were involved with response to steroid hormone stimulus (P=0.001849). FN1, LAMB3 and COL13A1 were enriched in cell adhesion (P=0.011121; [Table I](#tI-mmr-14-06-5041){ref-type="table"}).

In addition, two significant pathways were enriched for the common DEGs ([Table II](#tII-mmr-14-06-5041){ref-type="table"}). The ALDH1A3, AOX1, HGD, ADH1B and TPO genes were significantly involved in the tyrosine metabolism pathway (P=0.001). Another five common DEGs, including NRCAM, NCAM1, CLDN1, CLDN10 and CDH3, were enriched in the cell adhesion molecules pathway (P=0.05).

Interaction network analysis. There were eight common DEGs, of which MET, SERPINA1, LGALS3, FN1, LAMB3, KRT19 and COL13A1 were upregulated, and TNFRSF11B was downregulated) in the constructed subnetwork ([Fig. 3](#f3-mmr-14-06-5041){ref-type="fig"}). The FN1 DEG can interact with SERPINA1, LGALS3, TNFRSF11B and LAMB3. There were also pathway interactions between any two of the FN1, COL13A1 and LAMB3 DEGs.

Potential drug identification. The potential drugs for FN1 and SERPINA1 were examined further, as these two DEGs showed higher degrees in the interaction subnetwork and may be critical in the regulatory process. The results revealed that two drugs, lanoteplase and ocriplasmin, were found for FN1, and four potential drugs, β-mercaptoethanol, recombinant α 1-antitrypsin, PPL-100 and API, were found for SERPINA1 ([Table III](#tIII-mmr-14-06-5041){ref-type="table"}). Lanoteplase is currently under clinical investigation and ocriplasmin, whose pharmacological action involves the cleavage of fibronectin protein, has been approved by the Food and Drug Administration ([@b25-mmr-14-06-5041]). For SERPINA1, β-mercaptoethanol is during experimental stage and the other three drugs are under clinical investigation.

In addition, five potential drug-like compounds with binding energies below −8.4 were screened out from the diverse-lib database in MTiOpenScreen ([Table IV](#tIV-mmr-14-06-5041){ref-type="table"}). The 24350490 compound, with a binding energy of −8.7 kcal/mol, has six hydrogen bond acceptors and one hydrogen bond donor. Another compound, 17506143, with a binding energy of −8.6 kcal/mol has seven hydrogen bond acceptors and one hydrogen bond donor. The structural interactions between SERPINA1 and these two drug-like compounds are shown in [Fig. 4](#f4-mmr-14-06-5041){ref-type="fig"}. The binding pocket of SERPINA1 contained His209 and SER47.

Discussion
==========

In the present study, 167 genes were identified to be simultaneously differentially expressed in the tumor samples of GSE3467 and GSE3678. The subsequent pathway enrichment analysis revealed that ALDH1A3, AOX1, HGD, ADH1B and TPO were significantly involved in tyrosine metabolism. Several studies have revealed that the protooncogene, RET, which encodes a tyrosine kinase cell surface receptor, is involved in the oncogenesis of PTC by activating its tyrosine kinase, either by rearrangement or mutation ([@b26-mmr-14-06-5041],[@b27-mmr-14-06-5041]). It has been confirmed that the mRNA expression level of TPO is markedly suppressed leading to low thyroid peroxidase activity in PTC ([@b28-mmr-14-06-5041]). Thyroid peroxidase oxidizes iodide to form active iodine for addition onto tyrosine residues on thyroglobulin for the production of thyroid hormones ([@b29-mmr-14-06-5041]). In the present study, TPO was also found to be significantly downregulated in the tumor samples. Therefore, ALDH1A3, AOX1, HGD, ADH1B and TPO may be important in PTC via their involvement in the tyrosine metabolism pathway. By contrast, the NRCAM, NCAM1, CLDN1, CLDN10 and CDH3 were significantly enriched in the pathway of cell adhesion molecules. Molecules associated with cell adhesion, for example ICAM-1, are known to be involved in papillary growth and proliferative capacity ([@b30-mmr-14-06-5041]). The pathway enrichment analysis indicated that these common DEGs are involved in the pathogenesis and progression of PTC by regulating the pathways of tyrosine metabolism and cell adhesion molecules.

The representative subnetwork derived from the interaction network in the present study contained seven upregulated common DEGs (MET, SERPINA1, LGALS3, FN1, LAMB3 and COL13A1) and one downregulated DEG (TNFRSF11B). The MET, SERPINA1, LGALS3 and FN1 DEGs have been identified to be the potent biomarkers for PTC in previous studies ([@b31-mmr-14-06-5041],[@b32-mmr-14-06-5041]). The expression levels of FN1 and MET have been also reported to be upregulated in papillary thyroid carcinoma ([@b33-mmr-14-06-5041]). The functional enrichment analysis revealed that FN1 was significantly enriched in the plasma membrane, extracellular matrix and cell adhesion. Vasko *et al* ([@b34-mmr-14-06-5041]) showed that epithelial-to-mesenchymal transition is common in PTC invasion. It has been demonstrated that the genes differentially expressed in aggressive PTC are primarily associated with cell adhesion ([@b35-mmr-14-06-5041]). In addition, FN1 can interact with SERPINA1, LGALS3, TNFRSF11B and LAMB3, according to the subnetwork. These results suggested that FN1 might be involved in PCT by regulating the epithelial-to-mesenchymal transition and interacting with other DEGs. Lanoteplase and ocriplasmin were identified to be the potential drugs for FN1. It has been reported that fibronectin is upregulated in PTC ([@b36-mmr-14-06-5041]). Therefore, ocriplasmin may be of assistance in the prevention or treatment of PTC due to the cleavage of fibronectin.

Another common DEG with a higher degree, SERPINA1, was significantly associated with the functions of response to steroid hormone stimulus and response to estrogen stimulus in the present study. Vierlinger *et al* ([@b37-mmr-14-06-5041]) showed that SERPINA1 can be considered as a single marker for PTC. In papillary thyroid tumors and normal thyroid tissue, estrogen and progesterone receptors have been identified in thyroid tissue responsive to steroid hormones ([@b38-mmr-14-06-5041]). Kawabata *et al* ([@b39-mmr-14-06-5041]) reported estrogen receptor α (ERα) is expressed at high levels in papillary thyroid cancer, suggesting that ERα may be involved in the development, physiology and pathology of papillary carcinoma. Therefore, upregulated expression levels of SERPINA1 may contribute to the response to steroid hormones in PTC. In the present study, four potential drugs were selected for SERPINA1. As His209 and SER47 are critical for the binding of compounds by forming hydrogen bonds ([@b40-mmr-14-06-5041]), the amino acid around the pocket, which binds with compounds, may be critical for the function of SERPINA1. Therefore, β-mercaptoethanol and recombinant α 1-antitrypsin may be the potential drugs for PTC. However, there were a number of limitations to the present study. The gene expression profiles of PTC at different stages require further analysis. In addition, the gene and protein expression levels of important DEGs may be better confirmed using experimental studies.

In conclusion, the common DEGs identified from GSE3467 and GSE3678 were found to have the potential for use as candidate biomarkers for PTC. The upregulated expression levels of FN1 and SERPINA1 may be involved in PTC by regulating the epithelial-to-mesenchymal transition and response to steroid hormones, respectively. Furthermore, ocriplasmin, β-mercaptoethanol and recombinant α 1-antitrypsin may be potential drugs for the treatment of PTC. In further investigations, confirmation of the expression levels of important genes is required, as is the examination of PTC at different stages.

![Box-plots of standardized expression data of paired tumor and normal thyroid tissue samples. (A) GSE3467; (B) GSE3678).](MMR-14-06-5041-g00){#f1-mmr-14-06-5041}

![(A) Venn diagram of DEGs identified for the two data sets. (B) Correlation of the DEGs selected from GSE3467 with the DEGs selected from GSE3678. DEGs, differentially expressed genes.](MMR-14-06-5041-g01){#f2-mmr-14-06-5041}

![Constructed interaction sub-network. The black nodes indicate the differentially expressed genes. The red and blue lines represent the physical interactions and pathway interactions, respectively. The grey nodes represent genes that can be regulated by the DEGs or that link the DEGs together.](MMR-14-06-5041-g02){#f3-mmr-14-06-5041}

![Structural interactions between *SERPINA1* and the drug-like compounds, (A) 24350490 and (B) 17506143. The green dashed lines represent hydrogen bonds.](MMR-14-06-5041-g03){#f4-mmr-14-06-5041}

###### 

Top ten enriched GO terms in the CC, MF and BP categories for the common differentially expressed genes.

  Category   ID           Term                                                      Count   Genes                                                                                                                                                P-value
  ---------- ------------ --------------------------------------------------------- ------- ---------------------------------------------------------------------------------------------------------------------------------------------------- ----------
  CC         GO:0044459   Plasma membrane part                                      40      *GPR125, STARD13, NRCAM, SDPR, TPO, PLA2R1, ENTPD1, DPP4, FN1, GHR, COL13A1, MET, SLC34A2...*                                                        2.60E-05
  CC         GO:000998    Cell surface                                              13      *SCUBE3, GPR125, KIT, NCAM1, NRCAM, CD36, GPM6A, LAYN, CDON, TGFA, TPO, DPP4, GHR*                                                                   9.53E-05
  CC         GO:0005886   Plasma membrane                                           54      *GABRB3, TPO, TGFA, SLC4A4, GHR, PSD3, LIFR, SLC34A2, FN1, MUC1, COL13A1, MET, SHANK2...*                                                            3.56E-04
  CC         GO:0044420   Extracellular matrix part                                 7       *SMOC2, LAMB3, SCUBE3, COL13A1, TFF3, ENTPD1, FN1*                                                                                                   7.74E-04
  CC         GO:0030054   Cell junction                                             14      *GABRB3, GABRB2, COL13A1, PSD3, CLDN10, GABBR2, CDH3, ARHGAP24, SHANK2, CAMK2N1, *LAYN, CLDN1, DLG2, DPP4**                                          0.001052
  CC         GO:0044421   Extracellular region part                                 20      *SCUBE3, LGALS3, COL13A1, CHI3L1, KIT, SMOC2, LAMB3, TNFRSF11B, TGFA, TFF3, ANGPTL1, SERPINA1, CFI, GDF15, ENTPD1, PLA2R1, SFTPB, FN1, GHR, BMP8A*   0.001350
  CC         GO:0031012   Extracellular matrix                                      11      *SMOC2, LAMB3, TNFRSF11B, LGALS3, SCUBE3, COL13A1, CHI3L1, TFF3, SERPINA1, ENTPD1, FN1*                                                              0.001416
  CC         GO:0045211   Postsynaptic membrane                                     7       *GABRB3, GABRB2, PSD3, GABBR2, SHANK2, DLG2, CAMK2N1*                                                                                                0.001625
  CC         GO:0044456   Synapse part                                              9       *GABRB3, GABRB2, PSD3, GABBR2, LRRK2, SHANK2, DLG2, ITPR1, CAMK2N1*                                                                                  0.002101
  CC         GO:0016021   Integral to membrane                                      66      *GABBR2, TPO, DPP6, SLC4A4, DPP4, GHR, SEL1L3, ENTPD1, MUC1, MET, TMEM163, LAYN, BTBD11...*                                                          0.002429
  MF         GO:0043168   Anion binding                                             7       *SLC26A4, GABRB3, GABRB2, CLCNKB, CTSC, GHR, SLC34A2*                                                                                                2.15E-04
  MF         GO:0008509   Anion transmembrane transporter activity                  8       *SLC26A4, GABRB3, GABRB2, SLC26A7, ABCC3, CLCNKB, SLC4A4, SLC34A2*                                                                                   4.45E-04
  MF         GO:0015103   Inorganic anion transmembrane transporter activity        4       *SLC26A4, SLC26A7, SLC4A4, SLC34A2*                                                                                                                  0.003514
  MF         GO:0031404   Chloride ion binding                                      5       *SLC26A4, GABRB3, GABRB2, CLCNKB, CTSC*                                                                                                              0.005756
  MF         GO:0022838   Substrate specific channel activity                       10      *GABRB3, GPM6A, GABRB2, SLC26A7, AQP4, RYR2, CLCNKB, KCNJ2, KCNIP4, ITPR1*                                                                           0.012085
  MF         GO:0015267   Channel activity                                          10      *GABRB3, GPM6A, GABRB2, SLC26A7, AQP4 RYR2, CLCNKB, KCNJ2, KCNIP4, ITPR1*                                                                            0.014860
  MF         GO:0022803   Passive transmembrane transporter activity                10      *GABRB3, GPM6A, GABRB2, SLC26A7, AQP4, RYR2, CLCNKB, KCNJ2, KCNIP4, ITPR1*                                                                           0.015074
  MF         GO:0030246   Carbohydrate binding                                      9       *NOD1, LGALS3, GALNT7, LAYN, COL13A1, MRC2, CHI3L1, PLA2R1, FN1*                                                                                     0.017677
  MF         GO:0016917   GABA receptor activity                                    3       *GABRB3, GABRB2, GABBR2*                                                                                                                             0.020798
  MF         GO:0004714   Transmembrane receptor protein tyrosine kinase activity   4       *MET, KIT, IRS1, EPHB1*                                                                                                                              0.024558
  BP         GO:0007167   Enzyme linked receptor protein signaling pathway          11      *TIAM1, MET, LIFR, ANGPTL1, PPM1 L, KIT, GDF15, IRS1, EPHB1, CITED1, GHR*                                                                            0.001120
  BP         GO:0009725   Response to hormone stimulus                              10      *KRT19, TNFRSF11B, AVPR1A, FABP4, TFF3, SERPINA1, IRS1, CITED1, GHR, SLC34A2*                                                                        0.006298
  BP         GO:0043627   Response to estrogen stimulus                             6       *KRT19, TNFRSF11B, SERPINA1, CITED1, GHR, SLC34A2*                                                                                                   0.002681
  BP         GO:0048545   Response to steroid hormone stimulus                      8       *KRT19, TNFRSF11B, AVPR1A, FABP4, SERPINA1, CITED1, GHR, SLC34A2*                                                                                    0.001849
  BP         GO:0001570   Vasculogenesis                                            4       *HEY2, ZFPM2, CITED1, CITED2*                                                                                                                        0.006079
  BP         GO:0001666   Response to hypoxia                                       6       *PDE5A, RYR2, SERPINA1, ITPR1, DPP4, CITED2*                                                                                                         0.007532
  BP         GO:0042060   Wound healing                                             7       *CD36, SERPINA1, CDH3, ENTPD1, PAPSS2, PROS1, FN1*                                                                                                   0.007962
  BP         GO:0060350   Endochondral bone morphogenesis                           3       *COL13A1, RUNX2, GHR*                                                                                                                                0.009053
  BP         GO:0070482   Response to oxygen levels                                 6       *PDE5A, RYR2, SERPINA1, ITPR1, DPP4, CITED2*                                                                                                         0.009277
  BP         GO:0007155   Cell adhesion                                             14      *PLXNC1, MPZL2, COL13A1, CLDN10, CDH3, CDH6, NCAM1, NRCAM, LAMB3, CD36, CDON, CLDN1, ENTPD1, FN1*                                                    0.011121

GO, gene ontology; CC, cellular component; MF, molecular function; BP, biological process.

###### 

Enriched pathways for the common differentially expressed genes.

  Pathway_ID   Name                      Count   Genes                                 P-value
  ------------ ------------------------- ------- ------------------------------------- ---------
  hsa00350     Tyrosine metabolism       5       *ALDH1A3, AOX1, HGD, ADH1B, TPO*      0.001
  hsa04514     Cell adhesion molecules   5       *NRCAM, NCAM1, CLDN1, CLDN10, CDH3*   0.050

###### 

Potential drugs for *FN1* and *SERPINA1*

  Target       Drug                          State             Pharmacological action
  ------------ ----------------------------- ----------------- ------------------------
  *FN1*        Lanoteplase                   Investigational   Unknown
               Ocriplasmin                   Approved          Cleavage
  *SERPINA1*   β-mercaptoethanol             Experimental      Unknown
               Recombinant α 1-antitrypsin   Investigational   Unknown
               PPL-100                       Investigational   Unknown
               API                           Investigational   Unknown

###### 

Five drug-like compounds for *SERPINA1*.

  Compound   Energy (kcal/mol)   nRot (count)   Lead-like (yes/no)   HBA (count)   HBD (count)   LogP   MW (g/mol)   TPSA (Å^2^)
  ---------- ------------------- -------------- -------------------- ------------- ------------- ------ ------------ -------------
  24350490   −8.7                4              Y                    6             1             3.49   405.86       105.96
  17506143   −8.6                6              Y                    7             1             3.50   409.44       81.41
  26649374   −8.5                1              Y                    7             2             2.43   366.41       87.32
  49671559   −8.4                4              Y                    7             0             3.14   445.92       92.10
  26639702   −8.4                4              Y                    6             0             3.51   389.47       94.93

Energy, kacl/mol; nRo, number of rotatable bonds; Lead-like, drug lead-like or not; HBA, hydrogen bond acceptor; HBD, hydrogen bond donor; LogP, the solubility of a potential oral drug; MW, molecular weight; TPSA, topological polar surface area.
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